Proteomics International Laboratories (ASX:PIQ) issued a notice of termination to Sonic Healthcare USA, the US distributor of its diabetic kidney disease test PromarkerD, effective Tuesday, after not meeting certain milestones to commercialize the test kit, according to a Wednesday filing with the Australian bourse.
Following the termination, the diagnostic firm will now market and sell PromarkerD in the US via licensing deals with service providers, pathology laboratories, and/or direct-to-consumer/patient channels, the filing said.
The company will establish a code-compliant third-party reference laboratory ahead of the test kit's launch, the filing stated.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。